ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HRTX vs RNXT // FORWARD P/E MULTIPLE

Heron Therapeutics Inc. (NASDAQ) VS. RenovoRx Inc. (NASDAQ) • 15-METRIC TALLY: HRTX 4 — RNXT 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRTX VS. RNXT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HRTX RNXT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 73.30% 70.90% +2.40 HRTX /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -16.32% — TIE /fcf-yield <GO>
Operating Margin -1.60% -60.00% +58.40 HRTX /operating-margins <GO>
Net Profit Margin -12.90% -60.00% +47.10 HRTX /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.40 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 RNXT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.7 43.0 +0.70 HRTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $56.0M $56.9M -$837.8K RNXT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HRTX REV RNXT REV HRTX GROSS % RNXT GROSS % HRTX FCF RNXT FCF
FY 2025 $154.9M $1.1M 73.3% 70.9% -$27.9M -$11.0M
FY 2024 $144.3M $43.0K 73.2% 98.0% -$24.2M -$9.1M
FY 2023 $309.7M $31.9M — — -$58.8M -$10.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRTX // BETA —
RNXT // BETA —